MDCT上肝脏表面结节性定量评估对丙型肝炎病毒感染患者肝纤维化分期的准确性
研究纳入288例已知丙型肝炎病毒感染患者,采用半自动工具在MDCT上测量肝脏表面结节性(LSN)均值,并与METAVIR纤维化分期(F0-4)对比。LSN评分随纤维化分期增高而升高(F0=2.3±0.2至F4=3.8±1.0,p<0.001);识别显著纤维化(≥F2)、进展期纤维化(≥F3)和肝硬化(≥F4)的ROC AUC分别为0.88、0.89和0.90。结论认为MDCT上LSN评估可准确区分HCV患者的中期肝纤维化,尤其在较晚期水平。
要点
- LSN均值随METAVIR分期递增:F0=2.3±0.2、F1=2.4±0.3、F2=2.6±0.5、F3=2.9±0.6、F4=3.8±1.0(p<0.001)。
- 识别≥F2的LSN阈值2.80,敏感度0.68、特异度0.97,AUC 0.88。
- 识别≥F3阈值2.77(敏感度0.83、特异度0.85,AUC 0.89);识别≥F4阈值2.9(敏感度0.90、特异度0.80,AUC 0.90)。
核心结论
- MDCT上肝脏表面结节性评估可在HCV病因特异性队列中准确区分中期肝纤维化,尤其在更晚期水平。
研究设计与样本
- 研究为在已知HCV患者中评估MDCT半自动LSN测量工具的准确性的队列分析,共288例(79女/209男,平均年龄49.7岁),按METAVIR纤维化分期分层:F0(n=43)、F1(n=29)、F2(n=53)、F3(n=37)、F4(n=126);F0-3期基于CT前1年内活检结果,多数F4期患者也有1年内活检,其余病例有明确的临床/影像学肝硬化证据且未行活检。
关键影像表现/征象
- 沿肝脏前表面的连续LSN测量用于得出平均LSN评分。
- LSN评分随纤维化分期增高而升高:F0=2.3±0.2、F1=2.4±0.3、F2=2.6±0.5、F3=2.9±0.6、F4=3.8±1.0(p<0.001)。
诊断标准与关键数值
- 识别显著纤维化(≥F2):LSN阈值2.80,敏感度0.68、特异度0.97,ROC AUC 0.88。
- 识别进展期纤维化(≥F3):LSN阈值2.77,敏感度0.83、特异度0.85,ROC AUC 0.89。
- 识别肝硬化(≥F4):LSN阈值2.9,敏感度0.90、特异度0.80,ROC AUC 0.90。
临床应用与阅片要点
- 在HCV患者MDCT阅片时,可沿肝脏前表面进行半自动LSN测量并以均值评分辅助纤维化分期评估。
- LSN阈值2.80对≥F2特异度0.97但敏感度0.68,阈值2.9对≥F4敏感度0.90、特异度0.80,报告解读时需结合阈值对应的敏感度与特异度。
局限性
- F0-3期纤维化分期基于CT前1年内活检结果,多数F4期患者也有1年内活检,其余F4病例依据明确的临床/影像学肝硬化证据且未行活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate semi-automated measurement of liver surface nodularity (LSN) on MDCT in a cause-specific cohort of patients with chronic hepatitis C virus infection (HCV) for identification of hepatic fibrosis (stages F0-4).
METHODS: MDCT scans in patients with known HCV were evaluated with an independently validated, semi-automated LSN measurement tool. Consecutive LSN measurements along the anterior liver surface were performed to derive mean LSN scores. Scores were compared with METAVIR fibrosis stage (F0-4). Fibrosis stages F0-3 were based on biopsy results within 1 year of CT. Most patients with cirrhosis (F4) also had biopsy within 1 year; the remaining cases had unequivocal clinical/imaging evidence of cirrhosis and biopsy was not indicated.
RESULTS: 288 patients (79F/209M; mean age, 49.7 years) with known HCV were stratified based on METAVIR fibrosis stage: F0 (n = 43), F1 (n = 29), F2 (n = 53), F3 (n = 37), and F4 (n = 126). LSN scores increased with increasing fibrosis (mean: F0 = 2.3 ± 0.2, F1 = 2.4 ± 0.3, F2 = 2.6 ± 0.5, F3 = 2.9 ± 0.6, F4 = 3.8 ± 1.0; p < 0.001). For identification of significant fibrosis (≥ F2), advanced fibrosis (≥ F3), and cirrhosis (≥ F4), the ROC AUCs were 0.88, 0.89, and 0.90, respectively. The sensitivity and specificity for significant fibrosis (≥ F2) using LSN threshold of 2.80 were 0.68 and 0.97; for advanced fibrosis (≥ F3; threshold = 2.77) were 0.83 and 0.85; and for cirrhosis (≥ F4, LSN threshold = 2.9) were 0.90 and 0.80.
CONCLUSION: Liver surface nodularity assessment at MDCT allows for accurate discrimination of intermediate stages of hepatic fibrosis in a cause-specific cohort of patients with HCV, particularly at more advanced levels.
引用
- Lubner MG, Jones D, Said A, et al. Accuracy of liver surface nodularity quantification on MDCT for staging hepatic fibrosis in patients with hepatitis C virus. Abdom Radiol (NY). 2018. PMID: 29572714. doi:10.1007/s00261-018-1572-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。